Comparative Pharmacology
Head-to-head clinical analysis: TOBI versus TOBI PODHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBI versus TOBI PODHALER.
TOBI vs TOBI PODHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and incorporation of incorrect amino acids into the bacterial polypeptide chain.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA, inhibition of protein synthesis, and cell death. It is bactericidal against Pseudomonas aeruginosa.
4 to 6 mL of 300 mg/5 mL solution nebulized twice daily, 28 days on, 28 days off. Administer via PARI LC PLUS reusable nebulizer.
Inhalation of 4 capsules (112 mg) twice daily using the Podhaler device, 12 hours apart, for 28 days on/28 days off cycles.
None Documented
None Documented
Clinical Note
moderateCeftobiprole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftobiprole."
Clinical Note
moderateCeftobiprole + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftobiprole."
Clinical Note
moderateWarfarin + Ceftobiprole
"Warfarin may increase the anticoagulant activities of Ceftobiprole."
Clinical Note
moderatePhenprocoumon + Ceftobiprole
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged to 8-12 hours in renal impairment.
Terminal elimination half-life: approximately 3-4 hours in patients with cystic fibrosis. Clinically, following inhalation, systemic half-life does not directly guide dosing frequency due to local action in airways.
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Renal: approximately 90% of absorbed dose excreted unchanged in urine within 24 hours. Biliary/fecal: minimal (<5%).
Category C
Category C
Inhaled aminoglycoside antibiotic
Inhaled aminoglycoside antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftobiprole."